|1st July 2020||David G Foster||342||Grant/award etc.||$3.91||$1,337.22|
|30th June 2020||Mark J Enyedy||5,241||Grant/award etc.||$3.91||$20,492.31|
|30th June 2020||Thomas Ryll||5,241||Grant/award etc.||$3.91||$20,492.31|
|30th June 2020||Anna Berkenblit||3,047||Grant/award etc.||$3.91||$11,913.77|
|30th June 2020||Theresa Wingrove||2,593||Grant/award etc.||$3.91||$10,138.63|
|5th June 2020||Mark J Enyedy||13,700||Grant/award etc.||$0.00|
|2nd April 2020||David G Foster||5,448||Open or private sale||$3.43||$18,686.64|
|1st April 2020||David G Foster||18,160||Exercise of derivative||$0.00|
|24th February 2020||Mark J Enyedy||55,222||Open or private sale||$4.99||$275,557.78|
|24th February 2020||Theresa Wingrove||16,147||Open or private sale||$4.99||$80,573.53|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
ImmunoGen, Inc. was founded in March 1981 and is headquartered in Waltham, MA. Its product candidates include Mirvetuximab soravtansine, Coltuximbe ravtansin, IMGN7779 and IMGN632.